EL7.AI
Stocks•6 July 2026•
1 min read

Corbus Pharmaceuticals Appoints New CMO and Outlines Clinical Roadmap

Key Facts

1Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer effective August 3, 2026.
2The company plans to start the TEMPO-1 trial for CRB-701 in summer 2026 and expects topline data for obesity drug CRB-913 in late summer 2026.

In a move aimed at strengthening its scientific leadership and accelerating its drug development pipeline, Corbus Pharmaceuticals announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective August 3, 2026. According to reports, the company has outlined a clear roadmap for its clinical operations, planning to initiate the TEMPO-1 trial for CRB-701 in the summer of 2026. Additionally, the company expects to release topline data for its obesity candidate, CRB-913, in late summer of the same year.

These developments occur amidst an intense race within the biotech sector to develop obesity treatments, with firms like Viking Therapeutics and Structure Therapeutics vying for market share. Per market data, investors are closely monitoring Phase 1 and Phase 2 trial results for small and mid-cap biotech firms, as previous sector data indicates that success in obesity trials often triggers significant price volatility and strategic partnerships with major pharmaceutical companies.

Looking ahead, traders are awaiting the U.S. JOLTs Job Openings data on June 30, 2026, which may influence risk appetite across growth and biotech sectors.